Secukinumab in severe COVID-19 pneumonia: Does it have a clinical impact?
作者信息
Hasan Md Jahidul, Rabbani Raihan, Anam Ahmad Mursel, Huq Shihan Mahmud Redwanul
机构信息
Clinical Pharmacist (Critical Care and Infectious Diseases/Stewardship), Clinical Pharmacy Services, Department of Pharmacy, Square Hospitals Ltd., 18/F Bir Uttam Qazi Nuruzzaman Sarak, West Panthapath, Dhaka 1205, Bangladesh.
Internal Medicine and Intensive Care Unit, Department of Medical Services, Square Hospitals Ltd., 18/F Bir Uttam Qazi Nuruzzaman Sarak, West Panthapath, Dhaka 1205, Bangladesh.
出版信息
J Infect. 2021 Jul;83(1):e11-e13. doi: 10.1016/j.jinf.2021.05.011. Epub 2021 May 21.
Abstract
摘要
相似文献
1
Secukinumab in severe COVID-19 pneumonia: Does it have a clinical impact?司库奇尤单抗治疗重症新型冠状病毒肺炎：是否具有临床影响？
J Infect. 2021 Jul;83(1):e11-e13. doi: 10.1016/j.jinf.2021.05.011. Epub 2021 May 21.
2
Status of a real-life cohort of patients with moderate-to-severe plaque psoriasis treated with secukinumab and considerations on the use of biological agents in the Covid-19 era.中重度斑块状银屑病患者真实世界队列的现状，以及在新冠疫情时代使用生物制剂的相关考虑。
Expert Opin Biol Ther. 2020 Aug;20(8):829-830. doi: 10.1080/14712598.2020.1779217. Epub 2020 Jun 16.
3
COVID-19 in an elderly patient treated with secukinumab.一位接受司库奇尤单抗治疗的老年患者的新型冠状病毒肺炎
Dermatol Ther. 2020 Jul;33(4):e13580. doi: 10.1111/dth.13580. Epub 2020 May 27.
4
Implications of Interleukin-6 (IL-6)-blockade for severe COVID-19 infection in patients with Multiple Myeloma.白细胞介素-6（IL-6）阻断对多发性骨髓瘤患者严重新型冠状病毒肺炎感染的影响
Acta Biomed. 2021 May 12;92(2):e2021205. doi: 10.23750/abm.v92i2.11395.
5
Interleukin 6-blockade treatment for severe COVID-19 in two patients with multiple myeloma.白细胞介素6阻断疗法治疗两名多发性骨髓瘤患者的重症新型冠状病毒肺炎
Br J Haematol. 2020 Jul;190(1):e9-e11. doi: 10.1111/bjh.16787. Epub 2020 May 18.
6
Interleukin 6 levels after tocilizumab administration in transplant recipients with COVID-19.托珠单抗治疗新型冠状病毒肺炎移植受者后的白细胞介素6水平
Kidney Int. 2020 Oct;98(4):1054. doi: 10.1016/j.kint.2020.06.025. Epub 2020 Jul 8.
7
Is IL-6 the Right Target in COVID-19 Severe Pneumonia?白细胞介素-6是新冠重症肺炎的正确治疗靶点吗？
Am J Respir Crit Care Med. 2021 Jan 1;203(1):139-140. doi: 10.1164/rccm.202007-2924LE.
8
Treating multidrug-resistant psoriasis with brodalumab, apremilast, methotrexate and prednisone combination therapy in the COVID-19 pandemic.在新冠疫情期间使用布罗达单抗、阿普斯特、甲氨蝶呤和泼尼松联合疗法治疗耐多药银屑病
Dermatol Ther. 2020 Nov;33(6):e14464. doi: 10.1111/dth.14464. Epub 2020 Nov 8.
9
Elevated interleukin-6 and severe COVID-19: A meta-analysis.白细胞介素-6升高与重症新型冠状病毒肺炎：一项荟萃分析。
J Med Virol. 2020 Nov;92(11):2283-2285. doi: 10.1002/jmv.25948. Epub 2020 Jun 2.
10
Tocilizumab in SARS-CoV-2 Patients with the Syndrome of Cytokine Storm: A Narrative Review.托珠单抗治疗细胞因子风暴综合征的 SARS-CoV-2 患者：一项叙述性综述。
Rev Recent Clin Trials. 2021;16(2):138-145. doi: 10.2174/1574887115666200917110954.
引用本文的文献
1
Bridging worlds: a narrative review of IL-17 at the crossroads of inflammation and thrombosis.跨越界限：关于白细胞介素-17在炎症与血栓形成交叉点的叙述性综述
Inflamm Res. 2025 Sep 4;74(1):118. doi: 10.1007/s00011-025-02081-w.
2
COVID-19: A Disease Driven by Protease/Antiprotease Imbalance? A Specific Review Five Years into the Pandemic.新冠病毒病：一种由蛋白酶/抗蛋白酶失衡驱动的疾病？大流行五年后的专题综述
Infect Drug Resist. 2025 Aug 8;18:3967-3975. doi: 10.2147/IDR.S541205. eCollection 2025.
3
Weathering the Storm: How Age and Biologics Influence the COVID-19 Cytokine Surge.经受住风暴：年龄和生物制剂如何影响COVID-19细胞因子风暴
Pathogens. 2025 Apr 3;14(4):346. doi: 10.3390/pathogens14040346.
4
[Hidradenitis suppurativa, report with dual therapy: small molecules and biological therapy].[化脓性汗腺炎，小分子与生物疗法联合治疗的报告]
Rev Med Inst Mex Seguro Soc. 2025 Mar 3;63(2):e6596. doi: 10.5281/zenodo.14617170.
5
Controlling viral inflammatory lesions by rebalancing immune response patterns.通过重新平衡免疫反应模式来控制病毒炎症性病变。
Front Immunol. 2023 Aug 21;14:1257192. doi: 10.3389/fimmu.2023.1257192. eCollection 2023.
6
Severe acute respiratory syndrome coronavirus 2 infection: Role of interleukin-6 and the inflammatory cascade.严重急性呼吸综合征冠状病毒2感染：白细胞介素-6及炎症级联反应的作用
World J Virol. 2022 May 25;11(3):113-128. doi: 10.5501/wjv.v11.i3.113.
7
Therapeutic safety and efficacy of triple-immunosuppressants versus dual-immunosuppressants in severe-to-critical COVID-19: a prospective cohort study in Bangladesh.三重免疫抑制剂与双重免疫抑制剂在重症至危重症 COVID-19 患者中的治疗安全性和疗效：孟加拉国的一项前瞻性队列研究。
Ann Med. 2022 Dec;54(1):723-732. doi: 10.1080/07853890.2022.2039958.
本文引用的文献
1
Therapeutic Role of Tocilizumab in SARS-CoV-2-Induced Cytokine Storm: Rationale and Current Evidence.托珠单抗在 SARS-CoV-2 诱导的细胞因子风暴中的治疗作用：原理和现有证据。
Int J Mol Sci. 2021 Mar 17;22(6):3059. doi: 10.3390/ijms22063059.
2
IL-6 inhibition in the treatment of COVID-19: A meta-analysis and meta-regression.IL-6 抑制在 COVID-19 治疗中的作用：一项荟萃分析和荟萃回归研究。
J Infect. 2021 May;82(5):178-185. doi: 10.1016/j.jinf.2021.03.008. Epub 2021 Mar 18.
3
Severe covid-19 pneumonia: pathogenesis and clinical management.严重 COVID-19 肺炎：发病机制与临床管理。
BMJ. 2021 Mar 10;372:n436. doi: 10.1136/bmj.n436.
4
Role of IL-6 inhibitor in treatment of COVID-19-related cytokine release syndrome.白细胞介素-6 抑制剂在治疗 COVID-19 相关细胞因子释放综合征中的作用。
Int J Med Sci. 2021 Jan 21;18(6):1356-1362. doi: 10.7150/ijms.53564. eCollection 2021.
5
Additional baricitinib loading dose improves clinical outcome in COVID-19.额外的巴瑞替尼负荷剂量可改善新冠病毒病的临床结局。
Open Med (Wars). 2020 Dec 5;16(1):41-46. doi: 10.1515/med-2021-0010. eCollection 2021.
6
Inflammatory Cytokine: IL-17A Signaling Pathway in Patients Present with COVID-19 and Current Treatment Strategy.炎症细胞因子：COVID-19患者的IL-17A信号通路及当前治疗策略
J Inflamm Res. 2020 Oct 6;13:673-680. doi: 10.2147/JIR.S278335. eCollection 2020.
7
Coronavirus disease 2019 (COVID-19) in a patient with ankylosing spondylitis treated with secukinumab: a case-based review.以病例为基础的综述：使用司库奇尤单抗治疗的强直性脊柱炎患者的 2019 年冠状病毒病（COVID-19）。
Rheumatol Int. 2020 Oct;40(10):1707-1716. doi: 10.1007/s00296-020-04635-z. Epub 2020 Jun 26.
8
Interleukin-17: A potential therapeutic target in COVID-19.白细胞介素-17：新冠病毒病的一个潜在治疗靶点。
J Infect. 2020 Aug;81(2):e136-e138. doi: 10.1016/j.jinf.2020.05.072. Epub 2020 Jun 3.
Zotero 插件